<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03993847</url>
  </required_header>
  <id_info>
    <org_study_id>CLASSIC</org_study_id>
    <nct_id>NCT03993847</nct_id>
  </id_info>
  <brief_title>CLassification of Axial SpondyloarthritiS Inception Cohort</brief_title>
  <acronym>CLASSIC</acronym>
  <official_title>CLassification of Axial SpondyloarthritiS Inception Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spondyloarthritis Research and Treatment Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spondyloarthritis Research and Treatment Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A joint meeting of the ASAS (Assessment of Spondyloarthritis Internal Society) and SPARTAN&#xD;
      (Spondyloarthritis Research and Treatment Network) executive boards recommended that the&#xD;
      existing ASAS classification criteria for spondyloarthritis undergo further validation.&#xD;
&#xD;
      SPARTAN is in charge of conducting a a prospective study of a North American cohort of&#xD;
      patients presenting with undiagnosed active chronic back pain to rheumatologists in the US&#xD;
      and Canada, and one site in Mexico.&#xD;
&#xD;
      ASAS is in charge of conducting a similar study in Europe and other parts of the world.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall study design will follow a similar format to that used to develop the ASAS axial&#xD;
      SpA classification criteria. All consecutive patients referred to a rheumatologist with&#xD;
      current undiagnosed back pain of ≥3 months duration with onset ≤45 years of age will comprise&#xD;
      the prospective cohort. The sample size of 500 from North America (minimum of 300 from the&#xD;
      US) and 500 from outside North America is aimed at ensuring that a sufficient number of&#xD;
      patients will have axSpA and also permit the option to conduct 5-year follow up to determine&#xD;
      predictive validity of the classification criteria. The clinical assessment data, including&#xD;
      the history and physical examination, will be recorded by the rheumatologist in the&#xD;
      electronic case report form (eCRF). This will be accessed through an online portal.&#xD;
&#xD;
      The rheumatologist will complete 5 global assessments to determine the presence/absence of&#xD;
      axSpA. The first will be completed immediately after the first clinical assessment at the end&#xD;
      of the patient encounter and will incorporate details of the history and physical exam. This&#xD;
      is aimed at ascertaining which clinical features are considered most important in formulating&#xD;
      the rheumatologist's opinion regarding the diagnosis of axSpA. The second will be conducted&#xD;
      once the C-Reactive Protein (CRP), and HLA-B27 data are made available. The third will be&#xD;
      completed after the pelvic radiograph has been reviewed by the rheumatologist. The fourth&#xD;
      will be completed after the rheumatologist has reviewed the report of the pelvic MRI scan&#xD;
      provided by the local radiologist. The fifth will be completed after central review of the&#xD;
      anonymized radiograph and pelvic MRI scan and feedback to both the rheumatologist and&#xD;
      radiologist. In ASAS centers outside North America, it may not be possible to have an&#xD;
      assessment of each separate step as indicated if the rheumatologist already receives&#xD;
      information on lab and imaging results in the referral later. In that circumstance, only&#xD;
      global assessments 4 and 5 will be used as external standards. Patients will then be followed&#xD;
      according to the discretion of the rheumatologist and appropriate standards of clinical&#xD;
      practice. Patient contact information will be obtained and patient consent obtained through&#xD;
      the informed consent to allow contact with the patient after 5 years of follow up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Physician diagnosis of axial spondyloarthritis at the final diagnostic evaluation.</measure>
    <time_frame>6 weeks</time_frame>
    <description>Physician will answer Yes or No.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Prospective Cohort of Undiagnosed Back Pain</arm_group_label>
    <description>All consecutive patients referred to a rheumatologist with current undiagnosed back pain of ≥3 months duration with onset ≤45 years of age will comprise the prospective cohort.&#xD;
This is a classification study; no intervention will be administered</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Undiagnosed back and/or buttock pain with onset ≤45 years and duration ≥ 3 months&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Undiagnosed back and/or buttock pain&#xD;
&#xD;
          2. Back, buttock or hip discomfort in the week before the study visit&#xD;
&#xD;
          3. Discomfort in the back, buttocks, or hips that has lasted at least three months.&#xD;
&#xD;
          4. First symptoms of pain when patient was ≤ 45 years of age:&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a known rheumatologist confirmed diagnosis of spondyloarthritis at the&#xD;
             time of referral to the study-affiliated investigator.&#xD;
&#xD;
          2. Patients with a history of spinal trauma in the past 3 months.&#xD;
&#xD;
          3. Patients unable and/or unwilling to undergo MRI examination (embedded metallic&#xD;
             fragments, pacemaker, joint replacement or similar hardware, too large (over 350&#xD;
             pounds unless their MRI can scan larger patients), claustrophobic)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter P Maksymoywch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spondyloarthritis Research and Treatment Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rana Dadashova</last_name>
    <phone>587-400-9524</phone>
    <phone_ext>1003</phone_ext>
    <email>rana.dadashova@carearthritis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maida Wong, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sacramento VA Medical Center</name>
      <address>
        <city>Mather</city>
        <state>California</state>
        <zip>95655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Munira Ferdousi</last_name>
      <email>munira.ferdousi@va.gov</email>
    </contact>
    <investigator>
      <last_name>Siba Raychaudhuri, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center - Rheumatology Clinic</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Cheng</last_name>
      <email>Elizabeth.cheng@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Liron Caplan, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mari-Lynet Knight</last_name>
      <phone>203-785-2454</phone>
    </contact>
    <investigator>
      <last_name>Abhijeet Danve, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Keras</last_name>
      <phone>617-525-1061</phone>
    </contact>
    <investigator>
      <last_name>Joerg Ermann, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Plunket</last_name>
      <phone>617-358-9659</phone>
    </contact>
    <investigator>
      <last_name>Maureen Dubreuil, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delia Owens</last_name>
      <phone>601-815-9231</phone>
    </contact>
    <investigator>
      <last_name>Vikas Majithia, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James J. Peters VAMC</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrienne Perea</last_name>
      <email>Adrienne.Perea@va.gov</email>
    </contact>
    <investigator>
      <last_name>Kelly Steed, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saima Houl</last_name>
      <phone>216-444-7474</phone>
    </contact>
    <investigator>
      <last_name>Elaine Husni, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Nguyen</last_name>
      <phone>503-418-1065</phone>
    </contact>
    <investigator>
      <last_name>Atul Deodhar, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dallas VA Medical Center VANTHCS</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Guajardo</last_name>
      <email>erik.guajardo@va.gov</email>
    </contact>
    <investigator>
      <last_name>Andreas Reimold, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reyna Chavez</last_name>
      <phone>713-500-6870</phone>
    </contact>
    <investigator>
      <last_name>John D Reveille, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Rheumatology Associates</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Artus Health Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 7W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Patterson</last_name>
      <phone>613-738-8400</phone>
      <phone_ext>81630</phone_ext>
    </contact>
    <investigator>
      <last_name>Sibel Aydin, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Pereira</last_name>
      <email>daniel.pereira@uhnresearch.ca</email>
    </contact>
    <contact_backup>
      <last_name>Ammepa Anton</last_name>
      <email>Ammepa.Anton@uhnresearch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Vinod Chandran, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nigil Haroon, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CLIDITER</name>
      <address>
        <city>Mexico City</city>
        <state>Cdmx</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios de Investigacion Basica y Clinica, SC</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arturo Rivas Ramirez</last_name>
      <phone>+52-333-630-0946</phone>
    </contact>
    <investigator>
      <last_name>Ignacio Garcia Valladares, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 12, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spondyloarthritis</keyword>
  <keyword>SPARTAN</keyword>
  <keyword>ASAS</keyword>
  <keyword>SpA</keyword>
  <keyword>Undiagnosed Back Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

